http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 28 May 2026 06:56:08 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Intl+Ratings/Jefferies+Downgrades+CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+to+Hold/26560880.html <p>Jefferies analyst David Stanton downgraded CSL Ltd. (CSL:AU) (OTC: CSLLY) from Buy to Hold with a price target of AUD108.00 (from AUD195.00).</p><p>The analyst comments "In line with CSL Behring, growth in CSL Vifor appears difficult in the short term. CSL is seeing ongoing price competition, particularly from generic Venofer. We update medium-term CHF/US$ forex forecasts which negatively impacts Switzerland-based Vifor revenue/profit. We are now c10% below FactSet consensus for FY27E NPAT. We move to a peer-based SOTP multiple valuation (removing the DCF component). This implies a Hold recommendation (from Buy)."</p> http://www.streetinsider.com/Intl+Ratings/Jefferies+Downgrades+CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+to+Hold/26560880.html Thu, 28 May 2026 06:56:08 -0400 CSLLY http://www.streetinsider.com/Intl+Ratings/Jefferies+Downgrades+CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+to+Hold/26560880.html <p>Jefferies analyst David Stanton downgraded CSL Ltd. (CSL:AU) (OTC: CSLLY) from Buy to Hold with a price target of AUD108.00 (from AUD195.00).</p><p>The analyst comments "In line with CSL Behring, growth in CSL Vifor appears difficult in the short term. CSL is seeing ongoing price competition, particularly from generic Venofer. We update medium-term CHF/US$ forex forecasts which negatively impacts Switzerland-based Vifor revenue/profit. We are now c10% below FactSet consensus for FY27E NPAT. We move to a peer-based SOTP multiple valuation (removing the DCF component). This implies a Hold recommendation (from Buy)."</p> http://www.streetinsider.com/Intl+Ratings/Jefferies+Downgrades+CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+to+Hold/26560880.html Thu, 28 May 2026 06:56:08 -0400 CSLLY http://www.streetinsider.com/Downgrades/Jefferies+Downgrades+CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+to+Hold/26560880.html <p>Jefferies analyst David Stanton downgraded CSL Ltd. (CSL:AU) (OTC: CSLLY) from Buy to Hold with a price target of AUD108.00 (from AUD195.00).</p><p>The analyst comments "In line with CSL Behring, growth in CSL Vifor appears difficult in the short term. CSL is seeing ongoing price competition, particularly from generic Venofer. We update medium-term CHF/US$ forex forecasts which negatively impacts Switzerland-based Vifor revenue/profit. We are now c10% below FactSet consensus for FY27E NPAT. We move to a peer-based SOTP multiple valuation (removing the DCF component). This implies a Hold recommendation (from Buy)."</p> http://www.streetinsider.com/Downgrades/Jefferies+Downgrades+CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+to+Hold/26560880.html Thu, 28 May 2026 06:56:08 -0400 CSLLY http://www.streetinsider.com/Downgrades/Jefferies+Downgrades+CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+to+Hold/26560880.html <p>Jefferies analyst David Stanton downgraded CSL Ltd. (CSL:AU) (OTC: CSLLY) from Buy to Hold with a price target of AUD108.00 (from AUD195.00).</p><p>The analyst comments "In line with CSL Behring, growth in CSL Vifor appears difficult in the short term. CSL is seeing ongoing price competition, particularly from generic Venofer. We update medium-term CHF/US$ forex forecasts which negatively impacts Switzerland-based Vifor revenue/profit. We are now c10% below FactSet consensus for FY27E NPAT. We move to a peer-based SOTP multiple valuation (removing the DCF component). This implies a Hold recommendation (from Buy)."</p> http://www.streetinsider.com/Downgrades/Jefferies+Downgrades+CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+to+Hold/26560880.html Thu, 28 May 2026 06:56:08 -0400 CSLLY http://www.streetinsider.com/Analyst+Comments/Jefferies+Downgrades+CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+to+Hold/26560880.html <p>Jefferies analyst David Stanton downgraded CSL Ltd. (CSL:AU) (OTC: CSLLY) from Buy to Hold with a price target of AUD108.00 (from AUD195.00).</p><p>The analyst comments "In line with CSL Behring, growth in CSL Vifor appears difficult in the short term. CSL is seeing ongoing price competition, particularly from generic Venofer. We update medium-term CHF/US$ forex forecasts which negatively impacts Switzerland-based Vifor revenue/profit. We are now c10% below FactSet consensus for FY27E NPAT. We move to a peer-based SOTP multiple valuation (removing the DCF component). This implies a Hold recommendation (from Buy)."</p> http://www.streetinsider.com/Analyst+Comments/Jefferies+Downgrades+CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+to+Hold/26560880.html Thu, 28 May 2026 06:56:08 -0400 CSLLY http://www.streetinsider.com/Analyst+Comments/Jefferies+Downgrades+CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+to+Hold/26560880.html <p>Jefferies analyst David Stanton downgraded CSL Ltd. (CSL:AU) (OTC: CSLLY) from Buy to Hold with a price target of AUD108.00 (from AUD195.00).</p><p>The analyst comments "In line with CSL Behring, growth in CSL Vifor appears difficult in the short term. CSL is seeing ongoing price competition, particularly from generic Venofer. We update medium-term CHF/US$ forex forecasts which negatively impacts Switzerland-based Vifor revenue/profit. We are now c10% below FactSet consensus for FY27E NPAT. We move to a peer-based SOTP multiple valuation (removing the DCF component). This implies a Hold recommendation (from Buy)."</p> http://www.streetinsider.com/Analyst+Comments/Jefferies+Downgrades+CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+to+Hold/26560880.html Thu, 28 May 2026 06:56:08 -0400 CSLLY http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD175+at+UBS/26471521.html UBS analyst Laura Sutcliffe lowered the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD175.00 (from AUD205.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD175+at+UBS/26471521.html Tue, 12 May 2026 02:44:20 -0400 CSLLY http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD175+at+UBS/26471521.html UBS analyst Laura Sutcliffe lowered the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD175.00 (from AUD205.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD175+at+UBS/26471521.html Tue, 12 May 2026 02:44:20 -0400 CSLLY http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD175+at+UBS/26471521.html UBS analyst Laura Sutcliffe lowered the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD175.00 (from AUD205.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD175+at+UBS/26471521.html Tue, 12 May 2026 02:44:20 -0400 CSLLY http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD175+at+UBS/26471521.html UBS analyst Laura Sutcliffe lowered the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD175.00 (from AUD205.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD175+at+UBS/26471521.html Tue, 12 May 2026 02:44:20 -0400 CSLLY http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD205+at+UBS/26320050.html UBS analyst Laura Sutcliffe lowered the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD205.00 (from AUD235.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD205+at+UBS/26320050.html Thu, 16 Apr 2026 02:32:50 -0400 CSLLY http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD205+at+UBS/26320050.html UBS analyst Laura Sutcliffe lowered the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD205.00 (from AUD235.00) while maintaining a Buy rating. http://www.streetinsider.com/Intl+Ratings/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD205+at+UBS/26320050.html Thu, 16 Apr 2026 02:32:50 -0400 CSLLY http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD205+at+UBS/26320050.html UBS analyst Laura Sutcliffe lowered the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD205.00 (from AUD235.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD205+at+UBS/26320050.html Thu, 16 Apr 2026 02:32:50 -0400 CSLLY http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD205+at+UBS/26320050.html UBS analyst Laura Sutcliffe lowered the price target on CSL Ltd. (CSL:AU) (OTC: CSLLY) to AUD205.00 (from AUD235.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/CSL+Ltd.+%28CSL%3AAU%29+%28CSLLY%29+PT+Lowered+to+AUD205+at+UBS/26320050.html Thu, 16 Apr 2026 02:32:50 -0400 CSLLY http://www.streetinsider.com/Press+Releases/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html <div class="xn-content"> <p class="prntac">New <money>$1.5 billion</money> investment builds on over <money>$3 billion</money> already spent on CSL's <location value="LC/us" idsrc="xmltag.org" >U.S.</location> operations since 2018</p><p class="prntac">Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies and albumin through advanced manufacturing capabilities</p><p class="prntac"><person>Governor Pritzker</person>, local officials and CSL leadership underscore the expansion's role in supporting patients and strengthening the regional economy</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>March 9, 2026</chron></span> /PRNewswire/ -- CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in <location value="LU/us.il.kankee" idsrc="xmltag.org" >Kankakee, Illinois</location>. The expansion, http://www.streetinsider.com/Press+Releases/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html Mon, 09 Mar 2026 11:01:00 -0400 A.50201969 CSL CSLLY O.00673957 O.29426449 http://www.streetinsider.com/Press+Releases/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html <div class="xn-content"> <p class="prntac">New <money>$1.5 billion</money> investment builds on over <money>$3 billion</money> already spent on CSL's <location value="LC/us" idsrc="xmltag.org" >U.S.</location> operations since 2018</p><p class="prntac">Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies and albumin through advanced manufacturing capabilities</p><p class="prntac"><person>Governor Pritzker</person>, local officials and CSL leadership underscore the expansion's role in supporting patients and strengthening the regional economy</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>March 9, 2026</chron></span> /PRNewswire/ -- CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in <location value="LU/us.il.kankee" idsrc="xmltag.org" >Kankakee, Illinois</location>. The expansion, http://www.streetinsider.com/Press+Releases/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html Mon, 09 Mar 2026 11:01:00 -0400 A.50201969 CSL CSLLY O.00673957 O.29426449 http://www.streetinsider.com/Press+Releases/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html <div class="xn-content"> <p class="prntac">New <money>$1.5 billion</money> investment builds on over <money>$3 billion</money> already spent on CSL's <location value="LC/us" idsrc="xmltag.org" >U.S.</location> operations since 2018</p><p class="prntac">Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies and albumin through advanced manufacturing capabilities</p><p class="prntac"><person>Governor Pritzker</person>, local officials and CSL leadership underscore the expansion's role in supporting patients and strengthening the regional economy</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>March 9, 2026</chron></span> /PRNewswire/ -- CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in <location value="LU/us.il.kankee" idsrc="xmltag.org" >Kankakee, Illinois</location>. The expansion, http://www.streetinsider.com/Press+Releases/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html Mon, 09 Mar 2026 11:01:00 -0400 A.50201969 CSL CSLLY O.00673957 O.29426449 http://www.streetinsider.com/Press+Releases/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html <div class="xn-content"> <p class="prntac">New <money>$1.5 billion</money> investment builds on over <money>$3 billion</money> already spent on CSL's <location value="LC/us" idsrc="xmltag.org" >U.S.</location> operations since 2018</p><p class="prntac">Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies and albumin through advanced manufacturing capabilities</p><p class="prntac"><person>Governor Pritzker</person>, local officials and CSL leadership underscore the expansion's role in supporting patients and strengthening the regional economy</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>March 9, 2026</chron></span> /PRNewswire/ -- CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in <location value="LU/us.il.kankee" idsrc="xmltag.org" >Kankakee, Illinois</location>. The expansion, http://www.streetinsider.com/Press+Releases/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html Mon, 09 Mar 2026 11:01:00 -0400 A.50201969 CSL CSLLY O.00673957 O.29426449 http://www.streetinsider.com/Press+Releases/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html <div class="xn-content"> <p class="prntac">New <money>$1.5 billion</money> investment builds on over <money>$3 billion</money> already spent on CSL's <location value="LC/us" idsrc="xmltag.org" >U.S.</location> operations since 2018</p><p class="prntac">Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies and albumin through advanced manufacturing capabilities</p><p class="prntac"><person>Governor Pritzker</person>, local officials and CSL leadership underscore the expansion's role in supporting patients and strengthening the regional economy</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>March 9, 2026</chron></span> /PRNewswire/ -- CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in <location value="LU/us.il.kankee" idsrc="xmltag.org" >Kankakee, Illinois</location>. The expansion, http://www.streetinsider.com/Press+Releases/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html Mon, 09 Mar 2026 11:01:00 -0400 A.50201969 CSL CSLLY O.00673957 O.29426449 http://www.streetinsider.com/PRNewswire/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html <div class="xn-content"> <p class="prntac">New <money>$1.5 billion</money> investment builds on over <money>$3 billion</money> already spent on CSL's <location value="LC/us" idsrc="xmltag.org" >U.S.</location> operations since 2018</p><p class="prntac">Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies and albumin through advanced manufacturing capabilities</p><p class="prntac"><person>Governor Pritzker</person>, local officials and CSL leadership underscore the expansion's role in supporting patients and strengthening the regional economy</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>March 9, 2026</chron></span> /PRNewswire/ -- CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in <location value="LU/us.il.kankee" idsrc="xmltag.org" >Kankakee, Illinois</location>. The expansion, http://www.streetinsider.com/PRNewswire/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html Mon, 09 Mar 2026 11:01:00 -0400 A.50201969 CSL CSLLY O.00673957 O.29426449 http://www.streetinsider.com/PRNewswire/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html <div class="xn-content"> <p class="prntac">New <money>$1.5 billion</money> investment builds on over <money>$3 billion</money> already spent on CSL's <location value="LC/us" idsrc="xmltag.org" >U.S.</location> operations since 2018</p><p class="prntac">Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies and albumin through advanced manufacturing capabilities</p><p class="prntac"><person>Governor Pritzker</person>, local officials and CSL leadership underscore the expansion's role in supporting patients and strengthening the regional economy</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>March 9, 2026</chron></span> /PRNewswire/ -- CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in <location value="LU/us.il.kankee" idsrc="xmltag.org" >Kankakee, Illinois</location>. The expansion, http://www.streetinsider.com/PRNewswire/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html Mon, 09 Mar 2026 11:01:00 -0400 A.50201969 CSL CSLLY O.00673957 O.29426449 http://www.streetinsider.com/PRNewswire/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html <div class="xn-content"> <p class="prntac">New <money>$1.5 billion</money> investment builds on over <money>$3 billion</money> already spent on CSL's <location value="LC/us" idsrc="xmltag.org" >U.S.</location> operations since 2018</p><p class="prntac">Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies and albumin through advanced manufacturing capabilities</p><p class="prntac"><person>Governor Pritzker</person>, local officials and CSL leadership underscore the expansion's role in supporting patients and strengthening the regional economy</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>March 9, 2026</chron></span> /PRNewswire/ -- CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in <location value="LU/us.il.kankee" idsrc="xmltag.org" >Kankakee, Illinois</location>. The expansion, http://www.streetinsider.com/PRNewswire/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html Mon, 09 Mar 2026 11:01:00 -0400 A.50201969 CSL CSLLY O.00673957 O.29426449 http://www.streetinsider.com/PRNewswire/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html <div class="xn-content"> <p class="prntac">New <money>$1.5 billion</money> investment builds on over <money>$3 billion</money> already spent on CSL's <location value="LC/us" idsrc="xmltag.org" >U.S.</location> operations since 2018</p><p class="prntac">Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies and albumin through advanced manufacturing capabilities</p><p class="prntac"><person>Governor Pritzker</person>, local officials and CSL leadership underscore the expansion's role in supporting patients and strengthening the regional economy</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>March 9, 2026</chron></span> /PRNewswire/ -- CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in <location value="LU/us.il.kankee" idsrc="xmltag.org" >Kankakee, Illinois</location>. The expansion, http://www.streetinsider.com/PRNewswire/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html Mon, 09 Mar 2026 11:01:00 -0400 A.50201969 CSL CSLLY O.00673957 O.29426449 http://www.streetinsider.com/PRNewswire/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html <div class="xn-content"> <p class="prntac">New <money>$1.5 billion</money> investment builds on over <money>$3 billion</money> already spent on CSL's <location value="LC/us" idsrc="xmltag.org" >U.S.</location> operations since 2018</p><p class="prntac">Expansion will create at least 300 new jobs and enhance production of plasma-derived therapies and albumin through advanced manufacturing capabilities</p><p class="prntac"><person>Governor Pritzker</person>, local officials and CSL leadership underscore the expansion's role in supporting patients and strengthening the regional economy</p><p><span class="legendSpanClass"><location value="LU/us.pa.kinsia" idsrc="xmltag.org" >KING OF PRUSSIA, Pa.</location></span>, <span class="legendSpanClass"><chron>March 9, 2026</chron></span> /PRNewswire/ -- CSL (ASX:CSL; USOTC:CSLLY), a global biopharma leader, today broke ground for the expansion of its state-of-the-art manufacturing facility in <location value="LU/us.il.kankee" idsrc="xmltag.org" >Kankakee, Illinois</location>. The expansion, http://www.streetinsider.com/PRNewswire/CSL+announces+expansion+of+Illinois+plasma+therapy+manufacturing+facility/26130358.html Mon, 09 Mar 2026 11:01:00 -0400 A.50201969 CSL CSLLY O.00673957 O.29426449 http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html <p> NEW YORK--(BUSINESS WIRE)-- Deutsche Bank announced today its appointment as successor depositary bank for the sponsored American Depositary Receipt program of CSL Limited. </p><p> CSL Limited (OTC: CSLLY) is a global biopharma company with a dynamic portfolio of medicines. CSL uses its expertise in plasma-derived therapies, vaccines and biotechnology to deliver medicines for serious and complex diseases such as hemophilia, immune deficiencies, influenza, and iron deficiency anaemia. CSL employees over 29,000 people globally and is headquartered in Melbourne, Australia.* </p><p> In addition to specializing in administering cross-border equity structures such as New York Shares and American and Global Depositary Receipts, Deutsche http://www.streetinsider.com/Press+Releases/Deutsche+Bank+Appointed+as+Successor+Depositary+Bank+for+the+American+Depositary+Receipt+Program+of+CSL+Limited/25899522.html Tue, 27 Jan 2026 14:06:00 -0400 A.25829702 CSL CSLLY DB DBK O.00085204 O.00673957 O.05997221